PharmAla Biotech Completes Release Testing on Australian-Made LaNeo Capsules

Executive Summary

• PharmAla Biotech completed release testing of its first Australian‑made batch of LaNeo™ MDMA 40 mg capsules.
• The company delivered the first shipment of this product to the Orygen Institute for a Phase 3 trial on social anxiety in autistic youth, marking the final delivery under that contract.
• Management indicated an active production schedule for 2026, including development of 20 mg capsules and the first run of ALA‑002 capsules.

Key Details

• Completed release testing of Australian‑manufactured LaNeo™ MDMA 40 mg capsules – the first batch produced in Australia.
• First delivery of the Australian‑made product to Orygen Institute; shipment supports Orygen’s Phase 3 trial for social anxiety in autistic youth.
• This shipment is the final one under PharmAla’s contract with Orygen, concluding that agreement.
• COO Farnoud Kazemzadeh highlighted plans for an “active production schedule for 2026,” including:
• Development and release of 20 mg LaNeo™ MDMA capsules.
• Manufacture and encapsulation of the first run of ALA‑002 capsules.

Notable Quotes

• “PharmAla is pleased to have completed this first batch of material of Australian‑made materials in partnership with our colleagues at Cortexa… we are all the more excited to move forward into a very active production schedule for 2026.” – Farnoud Kazemzadeh, COO

Materiality Assessment: Non-Material – Positive (operational progress without disclosed financial impact).